4
Views
6
CrossRef citations to date
0
Altmetric
Original Article

5-Fluorouracil with Folinic Acid is Not Effective Against Metastatic Adenocarcinoma of the Lung

, , , , , , & show all
Pages 345-349 | Published online: 11 Jun 2009

References

  • Kris M G, Cohen E, Gralla R. An analysis of 134 Phase II Trials in non-small cell lung cancer. Proc IVth World Conference on Lung Cancer, Toronto, 1985
  • Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469–475
  • Doroshow J H, Bertrand M, Multhauf P, et al. Prospective randomized trial comparing 5-FU versus 5-FU and high-dose folinic acid for treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 1987; 6: 96, (abstr)
  • Petrelli N, Stablein D, Bruckner H, et al. A prospective randomized phase III trial of 5-fluorouracil versus 5FU + high dose leucovorin versus 5FU + low-dose leucovorin in patients with metastatic colorectal adenocarcinoma. A report of the Gastrointestinal Study Group. Proc Am Soc Clin Oncol 1988; 7: 94, (abst)
  • Santi D V, McHenry C S, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorouridylate. Biochemistry 1974; 13: 471–480
  • Marini G, Marpicati P, Zaniboni A, et al. Treatment of advanced breast cancer with 5-fluorouracil and high-dose folinic acid: Preliminary results. Chemioterapie 1985; 4(2)135–138
  • Fine S, Erlichman C, Kaizer L, et al. Phase II trial of 5FU and folinic acid as first line treatment for metastatic breast cancer. Proc Am Soc Clin Oncol 1988; 7: 161, (abstr)
  • Doroshow J, Leong L, Margolin K, et al. Effective salvage therapy for refractory metastatic breast cancer with high-dose continuous infusion folinic acid and intravenous bolus 5-fluorouracil. Proc Am Soc Clin Oncol 1988; 6: 129, (abstr)
  • Fox R M, Woods R L, Tattersall M H N, et al. Allopurinol modulation of fluorouracil toxicity. Cancer Chemother Pharmacol 1981; 5: 151–155
  • Selawry O S. The role of chemotherapy in the treatment of lung cancer. Sem Oncol 1974; 1(3)259–272
  • Sorensen J, Personal communication

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.